308 related articles for article (PubMed ID: 27822484)
1. Impact of Ivabradine on Inflammatory Markers in Chronic Heart Failure.
Rohm I; Kretzschmar D; Pistulli R; Franz M; Schulze PC; Stumpf C; Yilmaz A
J Immunol Res; 2016; 2016():6949320. PubMed ID: 27822484
[No Abstract] [Full Text] [Related]
2. Impact of Ivabradine on Health-Related Quality of Life of Patients with Ischaemic Chronic Heart Failure.
Sallam M; Al-Saadi T; Alshekaili L; Al-Zakwani I
Curr Vasc Pharmacol; 2016; 14(5):481-486. PubMed ID: 27145825
[TBL] [Abstract][Full Text] [Related]
3. Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice.
Zugck C; Martinka P; Stöckl G
Adv Ther; 2014 Sep; 31(9):961-74. PubMed ID: 25160945
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment with ivabradine over 12months in patients with chronic heart failure in clinical practice: Effect on symptoms, quality of life and hospitalizations.
Zugck C; Störk S; Stöckl G;
Int J Cardiol; 2017 Aug; 240():258-264. PubMed ID: 28408104
[TBL] [Abstract][Full Text] [Related]
5. Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure.
Bonnet D; Berger F; Jokinen E; Kantor PF; Daubeney PEF
J Am Coll Cardiol; 2017 Sep; 70(10):1262-1272. PubMed ID: 28859790
[TBL] [Abstract][Full Text] [Related]
6. Advances in the management of heart failure: the role of ivabradine.
Müller-Werdan U; Stöckl G; Werdan K
Vasc Health Risk Manag; 2016; 12():453-470. PubMed ID: 27895488
[TBL] [Abstract][Full Text] [Related]
7. Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure.
Jirak P; Fejzic D; Paar V; Wernly B; Pistulli R; Rohm I; Jung C; Hoppe UC; Schulze PC; Lichtenauer M; Yilmaz A; Kretzschmar D
Acta Pharmacol Sin; 2018 Jul; 39(7):1189-1196. PubMed ID: 29239349
[TBL] [Abstract][Full Text] [Related]
8. Quality of life improvement in older patients with heart failure initiated on ivabradine: Results from the UK multi-centre LIVE:LIFE prospective cohort study.
Zachariah D; Stevens D; Sidorowicz G; Spooner C; Rowell N; Taylor J; Kay R; Salek MS; Kalra PR;
Int J Cardiol; 2017 Dec; 249():313-318. PubMed ID: 29121732
[TBL] [Abstract][Full Text] [Related]
9. Ivabradine improves quality of life in subjects with chronic heart failure compared to treatment with β-blockers: results of a multicentric observational APULIA study.
Riccioni G; Masciocco L; Benvenuto A; Saracino P; De Viti D; Massari F; Meliota G; Buta F; Speziale G
Pharmacology; 2013; 92(5-6):276-80. PubMed ID: 24296869
[TBL] [Abstract][Full Text] [Related]
10. Characterizing patients with chronic heart failure in community care after hospitalization: a potential role for ivabradine.
Elder DH; Mohan M; Cochrane L; Charles H; Lang CC
Cardiovasc Ther; 2015 Jun; 33(3):104-8. PubMed ID: 25809454
[TBL] [Abstract][Full Text] [Related]
11. Prescribing patterns to optimize heart rate: analysis of 1,000 consecutive outpatient appointments to a single heart failure clinic over a 6-month period.
Dierckx R; Cleland JG; Parsons S; Putzu P; Pellicori P; Dicken B; Boyalla V; Clark AL
JACC Heart Fail; 2015 Mar; 3(3):224-30. PubMed ID: 25650369
[TBL] [Abstract][Full Text] [Related]
12. Role of ivabradine and heart rate lowering in chronic heart failure: guideline update.
Chow SL; Page RL; Depre C
Expert Rev Cardiovasc Ther; 2018 Jul; 16(7):515-526. PubMed ID: 29902387
[TBL] [Abstract][Full Text] [Related]
13. I(f) current inhibitor ivabradine in patients with idiopathic dilated cardiomyopathy: Impact on the exercise tolerance and quality of life.
Abdel-Salam Z; Rayan M; Saleh A; Abdel-Barr MG; Hussain M; Nammas W
Cardiol J; 2015; 22(2):227-32. PubMed ID: 25179314
[TBL] [Abstract][Full Text] [Related]
14. Ivabradine treatment prevents dobutamine-induced increase in heart rate in patients with acute decompensated heart failure.
Cavusoglu Y; Mert U; Nadir A; Mutlu F; Morrad B; Ulus T
J Cardiovasc Med (Hagerstown); 2015 Sep; 16(9):603-9. PubMed ID: 24922198
[TBL] [Abstract][Full Text] [Related]
15. [Ivabradine for Treatment of Heart Failure with Preserved Ejection Fraction].
Babushkina GV; Shaikhlislamova GI
Kardiologiia; 2020 Oct; 60(10):33-37. PubMed ID: 33228503
[TBL] [Abstract][Full Text] [Related]
16. [Comparative Evaluation of -blockers and If-Channel Inhibitor in Patients With Chronic Heart Failure and Preserved Left Ventricular Ejection Fraction].
Kanorsky SG; Borisenko YV
Kardiologiia; 2016 Feb; 56(2):24-29. PubMed ID: 28294745
[TBL] [Abstract][Full Text] [Related]
17. Cardiac and Hemodynamic Benefits: Mode of Action of Ivabradine in Heart Failure.
Pereira-Barretto AC
Adv Ther; 2015 Oct; 32(10):906-19. PubMed ID: 26521191
[TBL] [Abstract][Full Text] [Related]
18. Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial).
Böhm M; Robertson M; Ford I; Borer JS; Komajda M; Kindermann I; Maack C; Lainscak M; Swedberg K; Tavazzi L
Am J Cardiol; 2015 Dec; 116(12):1890-7. PubMed ID: 26508709
[TBL] [Abstract][Full Text] [Related]
19. Ivabradine.
Komajda M
Handb Exp Pharmacol; 2017; 243():167-175. PubMed ID: 27752846
[TBL] [Abstract][Full Text] [Related]
20. Ivabradine for the treatment of chronic heart failure.
Henri C; O'Meara E; De Denus S; Elzir L; Tardif JC
Expert Rev Cardiovasc Ther; 2016; 14(5):553-61. PubMed ID: 26967048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
